This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Paediatric Vaccine Market

Market Insights on Paediatric Vaccine covering sales outlook, demand forecast & up-to-date key trends

Paediatric Vaccine Market by Indication, Technology, Vaccine, End User & Region - Forecast 2022 - 2032

Paediatric Vaccine Market Snapshot (2022-2032)

[250 Pages Report] The global paediatric vaccine market is expected to enjoy a valuation of US$ 48.8 Bn by the end of the year 2022, and further expand at a CAGR of 12.7% to reach a valuation of US$ 160.7 Bn by the year 2032. According to the recent study by Future Market Insights, pneumococcal vaccine by indication is leading the market with a share of about 31.9% in the year 2021, within the global market.

Market Outlook:

Data Points

Market Insights

Market Value 2021

US$ 44.1 Bn

Market Value 2022

US$ 48.8 Bn

Market Value 2032

US$ 160.7 Bn

CAGR 2022-2032

12.7%

Market Share of Top 5 Countries

39.8%

Key Market Players

GlaaxoSmithKline Plc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immnunologicals, Catalent Inc, Robinson Pharma, Inc., Hunan Er-Kang Pharmaceutical Co., Ltd., Procaps, CAPTEK Softgel International Inc., Softcaps, Fuji Capsule Co., Ltd., Aenova Holding GmbH, Sirio Pharma Co., Ltd., Bahrain Pharma, Sinovac Biotech Ltd., and AstraZeneca plc.

Global demand for paediatric vaccines market is expected to grow due to increasing live births and increasing number of infectious diseases like pneumonia, malaria, diarrhoea, and tuberculosis.

Some major disease like Hepatitis A., Hepatitis B., HPV (human papillomavirus, polio, tetanus, and rubella majorly affect the paediatric population due to their weak immune system. Paediatric vaccines protect children to affect by such disease will further expand the market globally.

Customize this Report

Let us know your requirement to get
100% FREE customization

Sales Analysis Of Paediatric Vaccine Market From 2014 To 2021 Vs Market Outlook For 2022 To 2032

The market value for the paediatric vaccine is approximately 31.9% of the overall US$ 138.7 Bn of the global vaccines market in 2021.

The sales of paediatric vaccine expanded at a CAGR of 9.4% from 2014 to 2021, owing to the advent of the COVID-19 global pandemic.

Due to the steadily growing demand, manufacturers in the industry are concentrating more on paediatric vaccines. Globally, numerous infections are transmitted, and children's weak immune system makes them more susceptible to infections. The market for paediatric vaccines is expanding globally as a result of this factor.

There is an increasing development of vaccinations using cutting-edge technology.  For instance, Merck reported on the immunogenicity, safety, and tolerability of VAXNEUVANCETM (Pneumococcal 15-valent conjugate vaccine) in healthy new-borns enrolled between 42 and 90 days of age.

Manufacturers of paediatric vaccinations are working to create combination vaccines for diseases like attenuated vaccine and inactivated or killed vaccine. As a result, fewer institutional visits are required, which is intended to promote compliance with the immunisation programme.

Furthermore, players in the market are likely to concentrate their efforts on resolving various supply and production constraints in the vaccine industry to get an advantage in the paediatric vaccine market.

The newly developed COVID-19 vaccinations will likely start to be tested on children by several companies. For Instance, on 24 June 2022, in a report published by the Centers for Disease Control and Prevention, CDC Director suggested Moderna's COVID-19 vaccination be used as an alternative for children aged 6 through 17 years, in addition to its existing recommended usage in children 6 months through 5 years and adults 18 years and older.

Paediatric Vaccine Market Download Report Brochure

What Are The Key Opportunities For The Paediatric Vaccine Market Manufacturers?

The increasing investment of government and non – government organizations in increasing awareness, and favourable reimbursement policies are anticipated to boost the growth of the market.

Furthermore, increased emphasis on immunization programs to build awareness regarding the benefits of vaccination and increasing the accessibility of vaccines by making them available at affordable rates at government institutions will boost market expansion for paediatric vaccines.

Factors such as economic growth in emerging markets, increasing awareness of vaccines and immunization among the population, as parents are now more aware of vaccines and advanced features after use, are set to enhance the sales of the overall market.

Increasing research collaborations for the development of innovative vaccines and management of end users in order to enhance the reach of vaccines are important factors contributing to the growth of the global paediatric vaccine market.

The global paediatric vaccines market is anticipated to experience significant growth over the course of the assessment period as a result of recent developments and breakthroughs in next-generation rotavirus vaccines.

Furthermore, the development of new rotavirus vaccines has been significant in reducing the incidence of hospital admissions for diarrhoea among children five years old or younger. This is a major driving factor to boost the demand for paediatric vaccines.

Additionally, when incorporated into national immunization programs, rotavirus has shown to be a fully effective, long-term, and cost-effective treatment.  Hence, demand within the paediatric vaccine market is continuously surging.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What Are The Factors Restraining Demand For Paediatric Vaccines?

The high cost of vaccine refrigeration is anticipated to impede market expansion. Refrigeration is essential for vaccines to prevent mutations in their chemical structure, which are mostly caused by interaction with water and humidity and thus turn into useless drugs. About 80% of the expense of vaccinations goes into maintaining the cold chain from the point of production until the vaccines are administered.

Additionally, it is anticipated that the limited functional shelf life of several vaccines may restrain market expansion.

Lack of accessibility to paediatric medications in emerging nations due to inadequate healthcare infrastructure and less awareness are the factors restricting the market's growth.

Inappropriate or excessive vaccination doses can possibly cause a child's death. This factor will restrain the growth of paediatric vaccines in the forecast period. Additionally, doctors may administer vaccines with an expiration date in rural areas where there is a lack of public understanding regarding paediatric vaccines, which will diminish market demand.

Country-Wise Insights

What Makes the U.S. a Highly Lucrative Market for Paediatric Vaccines?

U.S. holds approximately 72.7% share in the North American market in 2021 and is projected to display growth at a lucrative CAGR of 11.9% during the forecast period.

Over the projection period, North America is anticipated to contribute the largest market share. This can be due to significant R&D expenditures and the general public's high awareness of various medical diseases. In the U.S healthcare facilities are increasing developing, and people are more aware of vaccines and immunization for children.

What Makes the China a Large Market for Paediatric Vaccine?

China holds a market share of around 5.6% in the global market in 2021.

The presence of market players in china is expanding and manufacturers generally focus on vaccines for the paediatric age group since after the COVID-19 outbreak.

For instance, on June 20202, a report published by the National Library of Medicine, Between January 16 and February 8, 2020, the Chinese Centers for Disease Control and Prevention received a nationwide case series of 2135 paediatric patients with COVID-19.

What is the Outlook of U.K. in the Paediatric Vaccine Market?

U.K. holds approximately 24.7% share in the European market in 2021 and is projected to display growth at a lucrative CAGR of 15.3% during the forecast period.

Campaigns to immunise people against infectious and chronic diseases were launched in the UK in the 20th century. The UK Health Security Agency (UK HSA) created a timeline of vaccine development over time as well as the start of routine immunisation programmes in the UK, which is also advantageous for the paediatric population.

The U.K. government took the lead in children's development and introduced a number of programmes for paediatric group immunisation.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-Wise Insights

Which Paediatric Vaccine Indication Is Driving Market Growth?

The pneumococcal vaccine by indication is expected to present a high growth, holding a market share of 31.9% in 2021, and the segment is expected to grow with a CAGR of about 15.0% in the global market during the forecast period.

The pneumococcus bacterium causes the pneumococcal disease. One of the age groups most at risk for the illness is children under 2 years old. Hence, CDC recommended that all children under the age of two should receive the pneumococcal conjugate vaccine on a regular basis.

Which Technology of Paediatric Vaccine is more in Focus Globally?

The conjugate vaccine technology targeted for paediatric vaccine holds the highest market share of 32.0% during the year 2021, with a CAGR of about 13.0% over the forecast years, in the global market.

Conjugate vaccines have been developed for children to trigger a significant immune response against bacterial capsular polysaccharides. Typhoid conjugate vaccine is recommended by the World Health Organization since it may be more effective and prevent typhoid fever in many children under the age of five.

Which Vaccine Largely aids towards the Growth of the Global Paediatric Vaccine Market?

Monovalent vaccines hold the highest market share of around 74.4% during the year 2021, with an expected growth at a CAGR of 11.2% by the end of the forecast period.

The adoption of monovalent vaccines is more as compared to multivalent vaccines. A monovalent vaccine is made to immunize against a single antigen or one particular pathogen. Monovalent vaccines like MUMPSVAX, ATTENUVAX and MERUVAX, are administered for disease like measles, mumps and rubella respectively.

Which End User Benefits the Most with the Sales of Paediatric Vaccine Globally?

Institutional health centers hold the highest market share of 72.3% during the year 2021. In these facilities, qualified healthcare personnel are conveniently accessible. This segment will continue to have the largest market share due to the availability of all vaccines on a single platform in such institutional health centres and the access to various government programmes.

Competitive landscape

The market for the production of paediatric vaccine is fragmented, with several competitors. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new product releases to satisfy consumer demand and increase their client base.

  • On 31 August 2022, Pfizer Inc and BioNTech SE announced the U.S. FDA immediate use of a booster dose of the Pfizer-BioNTech COVID-19 vaccine for people 12 years of age and older.
  • In June 2022, GlaaxoSmithKline Plc., declared that the US Food and Drug Administration (FDA) has authorized Priorix for active immunization for the prevention of mumps, measles, and rubella in people 12 months of age and older.

Similarly, recent developments related to companies manufacturing paediatric vaccines, have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope As Per Paediatric Vaccine Industry Analysis

Attribute

Details

Forecast Period

2022-2032

Historical Data Available for

2014-2022

Market Analysis

US$ Mn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa

Key Countries Covered

U.S., Canada Brazil, Mexico, Argentina, U.K., Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, North Africa

Key Market Segments Covered

Indication, Technology, Vaccine, End User and Region

Key Companies Profiled

  • GlaxoSmithKline Plc.
  • Merck & Co. Inc
  • Pfizer Inc.
  • Sanofi SA
  • Panacea Biotec
  • Zydus Cadila
  • Emergent BioSolutions Inc
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech and Indian Immnunologicals
  • Catalent Inc
  • Robinson Pharma, Inc.
  • Hunan Er-Kang Pharmaceutical Co., Ltd.
  • Procaps
  • CAPTEK Softgel International Inc.
  •  Softcaps, Fuji Capsule Co., Ltd.
  •  Aenova Holding GmbH
  • Sirio Pharma Co., Ltd.
  • Bahrain Pharma
  • Sinovac Biotech Ltd.
  • AstraZeneca plc

Pricing

Available upon Request

Key Market Segments Covered In Paediatric Vaccine Industry Research

By Indication:

  • Pneumococcal Conjugate Vaccine
  • DTP Vaccine
  • Influenza
  • Meningococcal Vaccine
  • Polio Vaccine
  • Rotavirus Vaccine
  • MMR Vaccine
  • Varicella Virus Vaccine

By Technology:

  • Live or Attenuated Vaccine
  • Inactivated or Killed Vaccine
  • Toxoid Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Recombinant Vector Vaccine

By Vaccine:

  • Monovalent Vaccines
  • Multivalent Vaccines

 By End User:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Health Centers

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global paediatric vaccine market is worth US$ 44.2 Bn in 2021 and is set to expand 3.3X over the next ten years.

New vaccine launches, rising diseases like typhoid, pneumonia and rubella among children, and awareness among people, are some of the key trends in this market.

GlaaxoSmithKline Plc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, Panacea Biotec, Zydus Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immnunologicals, and Catalent Inc are some of the key players in paediatric vaccine industry.

China accounts for about 5.6% of market share in 2021 in the global market.

The U.S., China, India, Canada and U.K. are expected to drive demand for the paediatric vaccine industry.

North America is one of the key markets for paediatric vaccine, with the U.S. accounting for about 72.7% of the North American paediatric vaccine market in the year 2021.

Paediatric vaccine is mostly produced in the U.S, and Canada.

From 2014-2021, the market for paediatric vaccine expanded at the rate of 9.4%.

India accounts for about 23.6% of market share in 2021 in the South Asian market and is projected to grow with a CAGR of 18.3% in the forecast period.

Demand for paediatric vaccine in Japan is expected to register a growth of 6.3% over the next ten years.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage/ Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Development/Innovation Trends

4. Key Success Factors

    4.1. Technology Roadmap

    4.2. PESTEL Analysis

    4.3. Porter’s Analysis

    4.4. Indication Features/ USPs

    4.5. Key Promotional Strategies, By Key Manufacturers

    4.6. Regulatory Landscape

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure

        5.1.3. Global Vaccines Market Overview

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Key Player’s Historic Growth

        5.2.2. Growing Prevalence of Chronic and Infectious Diseases

        5.2.3. Rise in Government and Non-Government Funding for the Development of Novel Vaccines

        5.2.4. New Product Launches / Approvals

        5.2.5. Growing Initiatives for Immunization Awareness

        5.2.6. Rising Approvals for Drugs and Biologics

        5.2.7. Impact of Availability of Biosimilar

        5.2.8. Technological Advancements

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis – Impact Assessment

    6.1. COVID-19 and Impact Analysis

        6.1.1. By Indication

        6.1.2. By Technology

        6.1.3. By Vaccine

        6.1.4. By End User

        6.1.5. By Region

    6.2. 2021 Market Scenario

7. Global Paediatric Vaccine Market Demand Value or Size (US$ Mn) Analysis 2014 – 2021 and Forecast, 2022–2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2014 – 2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Paediatric Vaccine Market Analysis 2014– 2021 and Forecast 2022–2032, By Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By indication, 2014 – 2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022–2032

        8.3.1. Pneumococcal Conjugate Vaccine

        8.3.2. DTP Vaccine

        8.3.3. Influenza

        8.3.4. Meningococcal Vaccine

        8.3.5. Polio Vaccine

        8.3.6. Rotavirus Vaccine

        8.3.7. MMR Vaccine

        8.3.8. Varicella Virus Vaccine

    8.4. Market Attractiveness Analysis By Indication

9. Global Paediatric Vaccine Market Analysis 2014– 2021 and Forecast 2022–2032, By Technology

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) By Technology, 2014 – 2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Technology, 2022–2032

        9.3.1. Live or Attenuated Vaccine

        9.3.2. Inactivated or Killed Vaccine

        9.3.3. Toxoid Vaccine

        9.3.4. Conjugate Vaccine

        9.3.5. Subunit Vaccine

        9.3.6. Recombinant Vector Vaccine

    9.4. Market Attractiveness Analysis By Indication

10. Global Paediatric Vaccine Market Analysis 2014– 2021 and Forecast 2022–2032, By Vaccine

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) By Vaccine, 2014 – 2021

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Vaccine, 2022–2032

        10.3.1. Monovalent Vaccines

        10.3.2. Multivalent Vaccines

    10.4. Market Attractiveness Analysis By Vaccine

11. Global Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032, By End User

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) By End User, 2014 – 2021

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Institutional Health Centers

    11.4. Market Attractiveness Analysis By End User

12. Global Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032, By Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis by Region, 2014 – 2021

    12.3. Current Market Size (US$ Mn) and Forecast by Region, 2022–2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Indication

        13.3.3. By Technology

        13.3.4. By Vaccine

        13.3.5. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Indication

        13.4.3. By Technology

        13.4.4. By Vaccine

        13.4.5. By End User

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. U.S. Paediatric Vaccine Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Indication

                13.8.1.2.2. By Technology

                13.8.1.2.3. By Vaccine

                13.8.1.2.4. By End User

        13.8.2. Canada Paediatric Vaccine Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Indication

                13.8.2.2.2. By Technology

                13.8.2.2.3. By Vaccine

                13.8.2.2.4. By End User

14. Latin America Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. Mexico

            14.3.1.2. Brazil

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Indication

        14.3.3. By Technology

        14.3.4. By Vaccine

        14.3.5. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Indication

        14.4.3. By Technology

        14.4.4. By Vaccine

        14.4.5. By End User

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Mexico Paediatric Vaccine Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Indication

                14.8.1.2.2. By Technology

                14.8.1.2.3. By Vaccine

                14.8.1.2.4. By End User

        14.8.2. Brazil Paediatric Vaccine Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Indication

                14.8.2.2.2. By Technology

                14.8.2.2.3. By Vaccine

                14.8.2.2.4. By End User

        14.8.3. Argentina Paediatric Vaccine Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Indication

                14.8.3.2.2. By Technology

                14.8.3.2.3. By Vaccine

                14.8.3.2.4. By End User

15. Europe Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    15.3. Current and Future Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Indication

        15.3.3. By Technology

        15.3.4. By Vaccine

        15.3.5. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Indication

        15.4.3. By Technology

        15.4.4. By Vaccine

        15.4.5. By End User

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. Germany Paediatric Vaccine Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Indication

                15.8.1.2.2. By Technology

                15.8.1.2.3. By Vaccine

                15.8.1.2.4. By End User

        15.8.2. Italy Paediatric Vaccine Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Indication

                15.8.2.2.2. By Technology

                15.8.2.2.3. By Vaccine

                15.8.2.2.4. By End User

        15.8.3. France Paediatric Vaccine Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Indication

                15.8.3.2.2. By Technology

                15.8.3.2.3. By Vaccine

                15.8.3.2.4. By End User

        15.8.4. U.K. Paediatric Vaccine Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Indication

                15.8.4.2.2. By Technology

                15.8.4.2.3. By Vaccine

                15.8.4.2.4. By End User

        15.8.5. Spain Paediatric Vaccine Market Analysis

            15.8.5.1. Introduction

            15.8.5.2. Market Analysis and Forecast by Market Taxonomy

                15.8.5.2.1. By Indication

                15.8.5.2.2. By Technology

                15.8.5.2.3. By Vaccine

                15.8.5.2.4. By End User

        15.8.6. BENELUX Paediatric Vaccine Market Analysis

            15.8.6.1. Introduction

            15.8.6.2. Market Analysis and Forecast by Market Taxonomy

                15.8.6.2.1. By Indication

                15.8.6.2.2. By Technology

                15.8.6.2.3. By Vaccine

                15.8.6.2.4. By End User

        15.8.7. Russia Paediatric Vaccine Market Analysis

            15.8.7.1. Introduction

            15.8.7.2. Market Analysis and Forecast by Market Taxonomy

                15.8.7.2.1. By Indication

                15.8.7.2.2. By Technology

                15.8.7.2.3. By Vaccine

                15.8.7.2.4. By End User

16. East Asia Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    16.3. Current and Future Market Size (US$ Mn and Forecast by Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Indication

        16.3.3. By Technology

        16.3.4. By Vaccine

        16.3.5. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Indication

        16.4.3. By Indication

        16.4.4. By Vaccine

        16.4.5. By End User

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. China Paediatric Vaccine Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Indication

                16.8.1.2.2. By Technology

                16.8.1.2.3. By Vaccine

                16.8.1.2.4. By End User

        16.8.2. Japan Paediatric Vaccine Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Indication

                16.8.2.2.2. By Technology

                16.8.2.2.3. By Vaccine

                16.8.2.2.4. By End User

        16.8.3. South Korea Paediatric Vaccine Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Indication

                16.8.3.2.2. By Technology

                16.8.3.2.3. By Vaccine

                16.8.3.2.4. By End User

17. South Asia Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend by Market Taxonomy, 2014 – 2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. India

            17.3.1.2. Indonesia

            17.3.1.3. Malaysia

            17.3.1.4. Thailand

            17.3.1.5. Rest of South Asia

        17.3.2. By Indication

        17.3.3. By Technology

        17.3.4. By Vaccine

        17.3.5. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Indication

        17.4.3. By Technology

        17.4.4. By Vaccine

        17.4.5. By End User

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. India Paediatric Vaccine Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Indication

                17.8.1.2.2. By Technology

                17.8.1.2.3. By Vaccine

                17.8.1.2.4. By End User

        17.8.2. Indonesia Paediatric Vaccine Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Indication

                17.8.2.2.2. By Technology

                17.8.2.2.3. By Vaccine

                17.8.2.2.4. By End User

        17.8.3. Malaysia Paediatric Vaccine Market Analysis

            17.8.3.1. Introduction

            17.8.3.2. Market Analysis and Forecast by Market Taxonomy

                17.8.3.2.1. By Indication

                17.8.3.2.2. By Technology

                17.8.3.2.3. By Vaccine

                17.8.3.2.4. By End User

        17.8.4. Thailand Paediatric Vaccine Market Analysis

            17.8.4.1. Introduction

            17.8.4.2. Market Analysis and Forecast by Market Taxonomy

                17.8.4.2.1. By Indication

                17.8.4.2.2. By Technology

                17.8.4.2.3. By Vaccine

                17.8.4.2.4. By End User

18. Oceania Paediatric Vaccine Market 2014-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022–2032

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Indication

        18.3.3. By Technology

        18.3.4. By Vaccine

        18.3.5. By End User

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Indication

        18.4.3. By Technology

        18.4.4. By Vaccine

        18.4.5. By End User

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. Australia Paediatric Vaccine Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Indication

                18.8.1.2.2. By Technology

                18.8.1.2.3. By Vaccine

                18.8.1.2.4. By End User

        18.8.2. New Zealand Paediatric Vaccine Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Indication

                18.8.2.2.2. By Technology

                18.8.2.2.3. By Vaccine

                18.8.2.2.4. By End User

19. Middle East and Africa (MEA) Paediatric Vaccine Market Analysis 2014 – 2021 and Forecast 2022–2032

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Trend Analysis by Market Taxonomy, 2014 – 2021

    19.3. Current and Future Market Size (US$ Mn) and Forecast by Market Taxonomy, 2022–2032

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. Turkey

            19.3.1.3. South Africa

            19.3.1.4. North Africa

            19.3.1.5. Rest of Middle East and Africa

        19.3.2. By Indication

        19.3.3. By Indication

        19.3.4. By Vaccine

        19.3.5. By End User

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Indication

        19.4.3. By Technology

        19.4.4. By Vaccine

        19.4.5. By End User

    19.5. Market Trends

    19.6. Key Market Participants - Intensity Mapping

    19.7. Drivers and Restraints - Impact Analysis

    19.8. Country Level Analysis & Forecast

        19.8.1. GCC Countries Paediatric Vaccine Market Analysis

            19.8.1.1. Introduction

            19.8.1.2. Market Analysis and Forecast by Market Taxonomy

                19.8.1.2.1. By Indication

                19.8.1.2.2. By Technology

                19.8.1.2.3. By Vaccine

                19.8.1.2.4. By End User

        19.8.2. Turkey Paediatric Vaccine Market Analysis

            19.8.2.1. Introduction

            19.8.2.2. Market Analysis and Forecast by Market Taxonomy

                19.8.2.2.1. By Indication

                19.8.2.2.2. By Technology

                19.8.2.2.3. By Vaccine

                19.8.2.2.4. By End User

        19.8.3. South Africa Paediatric Vaccine Market Analysis

            19.8.3.1. Introduction

            19.8.3.2. Market Analysis and Forecast by Market Taxonomy

                19.8.3.2.1. By Indication

                19.8.3.2.2. By Technology

                19.8.3.2.3. By Vaccine

                19.8.3.2.4. By End User

        19.8.4. North Africa Paediatric Vaccine Market Analysis

            19.8.4.1. Introduction

            19.8.4.2. Market Analysis and Forecast by Market Taxonomy

                19.8.4.2.1. By Indication

                19.8.4.2.2. By Technology

                19.8.4.2.3. By Vaccine

                19.8.4.2.4. By End User

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Share Analysis of Top Players (%)

    20.3. Market Presence Analysis

        20.3.1. By Regional Footprint of Players

        20.3.2. Indication Footprint of Players

        20.3.3. Channel Footprint of Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. GlaxoSmithKline Plc.

            21.3.1.1. Overview

            21.3.1.2. Indication & Services Portfolio

            21.3.1.3. Key Financials

            21.3.1.4. SWOT Analysis

            21.3.1.5. Key Developments

            21.3.1.6. Sales Footprint

            21.3.1.7. Strategy Overview

                21.3.1.7.1. Marketing Strategy

                21.3.1.7.2. Indication Strategy

                21.3.1.7.3. Channel Strategy

        21.3.2. Merck & Co. Inc

            21.3.2.1. Overview

            21.3.2.2. Indication & Services Portfolio

            21.3.2.3. Key Financials

            21.3.2.4. SWOT Analysis

            21.3.2.5. Key Developments

            21.3.2.6. Sales Footprint

            21.3.2.7. Strategy Overview

                21.3.2.7.1. Marketing Strategy

                21.3.2.7.2. Indication Strategy

                21.3.2.7.3. Channel Strategy

        21.3.3. Pfizer Inc.

            21.3.3.1. Overview

            21.3.3.2. Indication & Services Portfolio

            21.3.3.3. Key Financials

            21.3.3.4. SWOT Analysis

            21.3.3.5. Key Developments

            21.3.3.6. Sales Footprint

            21.3.3.7. Strategy Overview

                21.3.3.7.1. Marketing Strategy

                21.3.3.7.2. Indication Strategy

                21.3.3.7.3. Channel Strategy

        21.3.4. Sanofi SA

            21.3.4.1. Overview

            21.3.4.2. Indication & Services Portfolio

            21.3.4.3. Key Financials

            21.3.4.4. SWOT Analysis

            21.3.4.5. Key Developments

            21.3.4.6. Sales Footprint

            21.3.4.7. Strategy Overview

                21.3.4.7.1. Marketing Strategy

                21.3.4.7.2. Indication Strategy

                21.3.4.7.3. Channel Strategy

        21.3.5. Panacea Biotec

            21.3.5.1. Overview

            21.3.5.2. Indication & Services Portfolio

            21.3.5.3. Key Financials

            21.3.5.4. SWOT Analysis

            21.3.5.5. Key Developments

            21.3.5.6. Sales Footprint

            21.3.5.7. Strategy Overview

                21.3.5.7.1. Marketing Strategy

                21.3.5.7.2. Indication Strategy

                21.3.5.7.3. Channel Strategy

        21.3.6. Zydus Cadila

            21.3.6.1. Overview

            21.3.6.2. Indication & Services Portfolio

            21.3.6.3. Key Financials

            21.3.6.4. SWOT Analysis

            21.3.6.5. Key Developments

            21.3.6.6. Sales Footprint

            21.3.6.7. Strategy Overview

                21.3.6.7.1. Marketing Strategy

                21.3.6.7.2. Indication Strategy

                21.3.6.7.3. Channel Strategy

        21.3.7. Emergent BioSolutions Inc

            21.3.7.1. Overview

            21.3.7.2. Indication & Services Portfolio

            21.3.7.3. Key Financials

            21.3.7.4. SWOT Analysis

            21.3.7.5. Key Developments

            21.3.7.6. Sales Footprint

            21.3.7.7. Strategy Overview

                21.3.7.7.1. Marketing Strategy

                21.3.7.7.2. Indication Strategy

                21.3.7.7.3. Channel Strategy

        21.3.8. Serum Institute of India Pvt. Ltd.

            21.3.8.1. Overview

            21.3.8.2. Indication & Services Portfolio

            21.3.8.3. Key Financials

            21.3.8.4. SWOT Analysis

            21.3.8.5. Key Developments

            21.3.8.6. Sales Footprint

            21.3.8.7. Strategy Overview

                21.3.8.7.1. Marketing Strategy

                21.3.8.7.2. Indication Strategy

                21.3.8.7.3. Channel Strategy

        21.3.9. Bharat Biotech and Indian Immnunologicals

            21.3.9.1. Overview

            21.3.9.2. Indication & Services Portfolio

            21.3.9.3. Key Financials

            21.3.9.4. SWOT Analysis

            21.3.9.5. Key Developments

            21.3.9.6. Sales Footprint

            21.3.9.7. Strategy Overview

                21.3.9.7.1. Marketing Strategy

                21.3.9.7.2. Indication Strategy

                21.3.9.7.3. Channel Strategy

        21.3.10. Catalent Inc

            21.3.10.1. Overview

            21.3.10.2. Indication & Services Portfolio

            21.3.10.3. Key Financials

            21.3.10.4. SWOT Analysis

            21.3.10.5. Key Developments

            21.3.10.6. Sales Footprint

            21.3.10.7. Strategy Overview

                21.3.10.7.1. Marketing Strategy

                21.3.10.7.2. Indication Strategy

                21.3.10.7.3. Channel Strategy

        21.3.11. Robinson Pharma, Inc.

            21.3.11.1. Overview

            21.3.11.2. Indication & Services Portfolio

            21.3.11.3. Key Financials

            21.3.11.4. SWOT Analysis

            21.3.11.5. Key Developments

            21.3.11.6. Sales Footprint

            21.3.11.7. Strategy Overview

                21.3.11.7.1. Marketing Strategy

                21.3.11.7.2. Indication Strategy

                21.3.11.7.3. Channel Strategy

        21.3.12. Hunan Er-Kang Pharmaceutical Co., Ltd.

            21.3.12.1. Overview

            21.3.12.2. Indication & Services Portfolio

            21.3.12.3. Key Financials

            21.3.12.4. SWOT Analysis

            21.3.12.5. Key Developments

            21.3.12.6. Sales Footprint

            21.3.12.7. Strategy Overview

                21.3.12.7.1. Marketing Strategy

                21.3.12.7.2. Indication Strategy

                21.3.12.7.3. Channel Strategy

        21.3.13. Procaps

            21.3.13.1. Overview

            21.3.13.2. Indication & Services Portfolio

            21.3.13.3. Key Financials

            21.3.13.4. SWOT Analysis

            21.3.13.5. Key Developments

            21.3.13.6. Sales Footprint

            21.3.13.7. Strategy Overview

                21.3.13.7.1. Marketing Strategy

                21.3.13.7.2. Indication Strategy

                21.3.13.7.3. Channel Strategy

        21.3.14. CAPTEK Softgel International Inc.

            21.3.14.1. Overview

            21.3.14.2. Indication & Services Portfolio

            21.3.14.3. Key Financials

            21.3.14.4. SWOT Analysis

            21.3.14.5. Key Developments

            21.3.14.6. Sales Footprint

            21.3.14.7. Strategy Overview

                21.3.14.7.1. Marketing Strategy

                21.3.14.7.2. Indication Strategy

                21.3.14.7.3. Channel Strategy

        21.3.15. Softcaps, Fuji Capsule Co., Ltd.

            21.3.15.1. Overview

            21.3.15.2. Indication & Services Portfolio

            21.3.15.3. Key Financials

            21.3.15.4. SWOT Analysis

            21.3.15.5. Key Developments

            21.3.15.6. Sales Footprint

            21.3.15.7. Strategy Overview

                21.3.15.7.1. Marketing Strategy

                21.3.15.7.2. Indication Strategy

                21.3.15.7.3. Channel Strategy

        21.3.16. Aenova Holding GmbH

            21.3.16.1. Overview

            21.3.16.2. Indication & Services Portfolio

            21.3.16.3. Key Financials

            21.3.16.4. SWOT Analysis

            21.3.16.5. Key Developments

            21.3.16.6. Sales Footprint

            21.3.16.7. Strategy Overview

                21.3.16.7.1. Marketing Strategy

                21.3.16.7.2. Indication Strategy

                21.3.16.7.3. Channel Strategy

        21.3.17. Sirio Pharma Co., Ltd.

            21.3.17.1. Overview

            21.3.17.2. Indication & Services Portfolio

            21.3.17.3. Key Financials

            21.3.17.4. SWOT Analysis

            21.3.17.5. Key Developments

            21.3.17.6. Sales Footprint

            21.3.17.7. Strategy Overview

                21.3.17.7.1. Marketing Strategy

                21.3.17.7.2. Indication Strategy

                21.3.17.7.3. Channel Strategy

        21.3.18. Bahrain Pharma

            21.3.18.1. Overview

            21.3.18.2. Indication & Services Portfolio

            21.3.18.3. Key Financials

            21.3.18.4. SWOT Analysis

            21.3.18.5. Key Developments

            21.3.18.6. Sales Footprint

            21.3.18.7. Strategy Overview

                21.3.18.7.1. Marketing Strategy

                21.3.18.7.2. Indication Strategy

                21.3.18.7.3. Channel Strategy

        21.3.19. Sinovac Biotech Ltd.

            21.3.19.1. Overview

            21.3.19.2. Indication & Services Portfolio

            21.3.19.3. Key Financials

            21.3.19.4. SWOT Analysis

            21.3.19.5. Key Developments

            21.3.19.6. Sales Footprint

            21.3.19.7. Strategy Overview

                21.3.19.7.1. Marketing Strategy

                21.3.19.7.2. Indication Strategy

                21.3.19.7.3. Channel Strategy

        21.3.20. AstraZeneca plc

            21.3.20.1. Overview

            21.3.20.2. Indication & Services Portfolio

            21.3.20.3. Key Financials

            21.3.20.4. SWOT Analysis

            21.3.20.5. Key Developments

            21.3.20.6. Sales Footprint

            21.3.20.7. Strategy Overview

                21.3.20.7.1. Marketing Strategy

                21.3.20.7.2. Indication Strategy

                21.3.20.7.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 02: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 03: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 04: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User

Table 05: Global Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Region

Table 06: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country

Table 07: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 08: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 09: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 10: North America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User

Table 11: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country

Table 12: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 13: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 14: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 15: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User

Table 16: Europe Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country

Table 17: Europe Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 18: Europe Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 19: Europe Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 20: Europe Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User

Table 21: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country

Table 22: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 23: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 24: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 25: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User

Table 26: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country

Table 27: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 28: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 29: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 30: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by End User

Table 31: Oceania Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country

Table 32: Oceania Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 33: Oceania Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 34: Oceania Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 35: Oceania Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User

Table 36: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Country

Table 37: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Analysis 2014–2021 and Forecast 2022–2032, by Indication

Table 38: Middle East & Africa Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Technology

Table 39: Middle East & Africa Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by Vaccine

Table 40: Middle East & Africa Paediatric Vaccines Market Analysis 2014–2021 and Forecast 2022–2032, by End User

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 02: Global Paediatric Vaccines Market Forecast & Y-o-Y Growth, 2022–2032

Figure 03: Global Paediatric Vaccines Market Absolute $ Opportunity (US$ Mn) Analysis, 2021–2032

Figure 04: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Indication

Figure 05: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Indication

Figure 06: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Indication

Figure 07: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Technology

Figure 08: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Technology

Figure 09: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Technology

Figure 10: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Vaccine

Figure 11: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Vaccine

Figure 12: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Vaccine

Figure 13: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by End User

Figure 14: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by End User

Figure 15: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by End User

Figure 16: Global Paediatric Vaccines Market Value Share (%) Analysis 2022 and 2032, by Region

Figure 17: Global Paediatric Vaccines Market Y-o-Y Growth (%) Analysis 2021-2032, by Region

Figure 18: Global Paediatric Vaccines Market Attractiveness Analysis 2022–2032, by Region

Figure 19: North America Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 20: North America Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032

Figure 21: North America Paediatric Vaccines Market Value Share, by Indication (2022 E)

Figure 22: North America Paediatric Vaccines Market Value Share, by Technology (2022 E)

Figure 23: North America Paediatric Vaccines Market Value Share, by Vaccine (2022 E)

Figure 24: North America Paediatric Vaccines Market Value Share, by End User (2022 E)

Figure 25: North America Paediatric Vaccines Market Value Share, by Country (2022 E)

Figure 26: North America Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032

Figure 27: North America Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032

Figure 28: North America Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032

Figure 29: North America Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032

Figure 30: North America Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032

Figure 31: U.S. Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 32: Global Vs. U.S. Growth Comparison

Figure 33: U.S. Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 34: U.S. Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 35: U.S. Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 36: U.S. Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 37: Canada Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 38: Global Vs. Canada. Growth Comparison

Figure 39: Canada Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 40: Canada Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 41: Canada Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 42: Canada Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 43: Latin America Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 44: Latin America Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032

Figure 45: Latin America Paediatric Vaccines Market Value Share, by Indication (2022 E)

Figure 46: Latin America Paediatric Vaccines Market Value Share, by Technology (2022 E)

Figure 47: Latin America Paediatric Vaccines Market Value Share, by Vaccine (2022 E)

Figure 48: Latin America Paediatric Vaccines Market Value Share, by End User (2022 E)

Figure 49: Latin America Paediatric Vaccines Market Value Share, by Country (2022 E)

Figure 50: Latin America Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032

Figure 51: Latin America Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032

Figure 52: Latin America Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032

Figure 53: Latin America Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032

Figure 54: Latin America Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032

Figure 55: Mexico Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 56: Global Vs Mexico Growth Comparison

Figure 57: Mexico Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 58: Mexico Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 59: Mexico Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 60: Mexico Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 61: Brazil Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 62: Global Vs. Brazil. Growth Comparison

Figure 63: Brazil Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 64: Brazil Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 65: Brazil Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 66: Brazil Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 67: Argentina Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 68: Global Vs Argentina Growth Comparison

Figure 69: Argentina Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 70: Argentina Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 71: Argentina Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 72: Argentina Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 73: Europe Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 74: Europe Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032

Figure 75: Europe Paediatric Vaccines Market Value Share, by Indication (2022 E)

Figure 76: Europe Paediatric Vaccines Market Value Share, by Technology (2022 E)

Figure 77: Europe Paediatric Vaccines Market Value Share, by Vaccine (2022 E)

Figure 78: Europe Paediatric Vaccines Market Value Share, by End User (2022 E)

Figure 79: Europe Paediatric Vaccines Market Value Share, by Country (2022 E)

Figure 80: Europe Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032

Figure 81: Europe Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032

Figure 82: Europe Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032

Figure 83: Europe Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032

Figure 84: Europe Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032

Figure 85: UK Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 86: Global Vs. UK Growth Comparison

Figure 87: UK Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 88: UK Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 89: UK Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 90: UK Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 91: Germany Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 92: Global Vs. Germany Growth Comparison

Figure 93: Germany Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 94: Germany Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 95: Germany Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 96: Germany Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 97: Italy Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 98: Global Vs. Italy Growth Comparison

Figure 99: Italy Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 100: Italy Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 101: Italy Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 102: Italy Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 103: France Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 104: Global Vs France Growth Comparison

Figure 105: France Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 106: France Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 107: France Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 108: France Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 109: Spain Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 110: Global Vs Spain Growth Comparison

Figure 111: Spain Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 112: Spain Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 113: Spain Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 114: Spain Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 115: Russia Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 116: Global Vs Russia Growth Comparison

Figure 117: Russia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 118: Russia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 119: Russia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 120: Russia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 121: BENELUX Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 122: Global Vs BENELUX Growth Comparison

Figure 123: BENELUX Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 124: BENELUX Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 125: BENELUX Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 126: BENELUX Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 127: East Asia Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 128: East Asia Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032

Figure 129: East Asia Paediatric Vaccines Market Value Share, by Indication (2022 E)

Figure 130: East Asia Paediatric Vaccines Market Value Share, by Technology (2022 E)

Figure 131: East Asia Paediatric Vaccines Market Value Share, by Vaccine (2022 E)

Figure 132: East Asia Paediatric Vaccines Market Value Share, by End User (2022 E)

Figure 133: East Asia Paediatric Vaccines Market Value Share, by Country (2022 E)

Figure 134: East Asia Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032

Figure 135: East Asia Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032

Figure 136: East Asia Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032

Figure 137: East Asia Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032

Figure 138: East Asia Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032

Figure 139: China Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 140: Global Vs. China Growth Comparison

Figure 141: China Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 142: China Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 143: China Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 144: China Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 145: Japan Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 146: Global Vs. Japan Growth Comparison

Figure 147: Japan Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 148: Japan Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 149: Japan Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 150: Japan Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 151: South Korea Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 152: Global Vs South Korea Growth Comparison

Figure 153: South Korea Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 154: South Korea Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 155: South Korea Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 156: South Korea Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 157: South Asia Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 158: South Asia Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032

Figure 159: South Asia Paediatric Vaccines Market Value Share, by Indication (2022 E)

Figure 160: South Asia Paediatric Vaccines Market Value Share, by Technology (2022 E)

Figure 161: South Asia Paediatric Vaccines Market Value Share, by Vaccine (2022 E)

Figure 162: South Asia Paediatric Vaccines Market Value Share, by End User (2022 E)

Figure 163: South Asia Paediatric Vaccines Market Value Share, by Country (2022 E)

Figure 164: South Asia Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032

Figure 165: South Asia Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032

Figure 166: South Asia Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032

Figure 167: South Asia Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032

Figure 168: South Asia Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032

Figure 169: India Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 170: Global Vs. India Growth Comparison

Figure 171: India Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 172: India Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 173: India Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 174: India Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 175: Indonesia Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 176: Global Vs. Indonesia Growth Comparison

Figure 177: Indonesia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 178: Indonesia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 179: Indonesia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 180: Indonesia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 181: Malaysia Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 182: Global Vs. Malaysia Growth Comparison

Figure 183: Malaysia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 184: Malaysia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 185: Malaysia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 186: Malaysia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 187: Thailand Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 188: Global Vs. Thailand Growth Comparison

Figure 189: Thailand Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 190: Thailand Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 191: Thailand Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 192: Thailand Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 193: Oceania Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 194: Oceania Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032

Figure 195: Oceania Paediatric Vaccines Market Value Share, by Indication (2022 E)

Figure 196: Oceania Paediatric Vaccines Market Value Share, by Technology (2022 E)

Figure 197: Oceania Paediatric Vaccines Market Value Share, by Vaccine (2022 E)

Figure 198: Oceania Paediatric Vaccines Market Value Share, by End User (2022 E)

Figure 199: Oceania Paediatric Vaccines Market Value Share, by Country (2022 E)

Figure 200: Oceania Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032

Figure 201: Oceania Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032

Figure 202: Oceania Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032

Figure 203: Oceania Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032

Figure 204: Oceania Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032

Figure 205: Australia Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 206: Global Vs. Australia Growth Comparison

Figure 207: Australia Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 208: Australia Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 209: Australia Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 210: Australia Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 211: New Zealand Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 212: Global Vs New Zealand Growth Comparison

Figure 213: New Zealand Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 214: New Zealand Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 215: New Zealand Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 216: New Zealand Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 217: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Analysis, 2014–2021

Figure 218: Middle East & Africa Paediatric Vaccines Market Value (US$ Mn) Forecast, 2022-2032

Figure 219: Middle East & Africa Paediatric Vaccines Market Value Share, by Indication (2022 E)

Figure 220: Middle East & Africa Paediatric Vaccines Market Value Share, by Technology (2022 E)

Figure 221: Middle East & Africa Paediatric Vaccines Market Value Share, by Vaccine (2022 E)

Figure 222: Middle East & Africa Paediatric Vaccines Market Value Share, by End User (2022 E)

Figure 223: Middle East & Africa Paediatric Vaccines Market Value Share, by Country (2022 E)

Figure 224: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Indication, 2022–2032

Figure 225: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Technology, 2022–2032

Figure 226: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Vaccine, 2022–2032

Figure 227: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by End User, 2022–2032

Figure 228: Middle East & Africa Paediatric Vaccines Market Attractiveness Analysis by Country, 2022–2032

Figure 229: GCC Countries Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 230: Global Vs GCC Countries Growth Comparison

Figure 231: GCC Countries Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 232: GCC Countries Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 233: GCC Countries Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 234: GCC Countries Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 235: Turkey Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 236: Global Vs. Turkey Growth Comparison

Figure 237: Turkey Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 238: Turkey Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 239: Turkey Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 240: Turkey Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 241: South Africa Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 242: Global Vs. South Africa Growth Comparison

Figure 243: South Africa Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 244: South Africa Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 245: South Africa Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 246: South Africa Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Figure 247: North Africa Paediatric Vaccines Market Value Proportion Analysis, 2021

Figure 248: Global Vs North Africa Growth Comparison

Figure 249: North Africa Paediatric Vaccines Market Share Analysis (%) by Indication, 2021 & 2032

Figure 250: North Africa Paediatric Vaccines Market Share Analysis (%) by Technology, 2021 & 2032

Figure 251: North Africa Paediatric Vaccines Market Share Analysis (%) by Vaccine, 2021 & 2032

Figure 252: North Africa Paediatric Vaccines Market Share Analysis (%) by End User, 2021 & 2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Attenuated Vaccines Market

Published : May 2022

Healthcare

Vaccines Market

Published : February 2022

Healthcare

Pneumococcal Vaccines Market

Published : September 2021

Google translate

Paediatric Vaccine Market